MX2020002884A - Método y composición neuroprotectora mejorada para tratar afecciones neurológicas. - Google Patents

Método y composición neuroprotectora mejorada para tratar afecciones neurológicas.

Info

Publication number
MX2020002884A
MX2020002884A MX2020002884A MX2020002884A MX2020002884A MX 2020002884 A MX2020002884 A MX 2020002884A MX 2020002884 A MX2020002884 A MX 2020002884A MX 2020002884 A MX2020002884 A MX 2020002884A MX 2020002884 A MX2020002884 A MX 2020002884A
Authority
MX
Mexico
Prior art keywords
treating neurological
neurological conditions
neuroprotective composition
disease
composition
Prior art date
Application number
MX2020002884A
Other languages
English (en)
Spanish (es)
Inventor
Otis C Addington
Robert A Newman
Donald C Lo
Linda S Kaltenbach
Original Assignee
Phoenix Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phoenix Biotechnology Inc filed Critical Phoenix Biotechnology Inc
Publication of MX2020002884A publication Critical patent/MX2020002884A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
MX2020002884A 2017-09-14 2018-09-04 Método y composición neuroprotectora mejorada para tratar afecciones neurológicas. MX2020002884A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762558631P 2017-09-14 2017-09-14
PCT/US2018/049358 WO2019055245A1 (en) 2017-09-14 2018-10-02 IMPROVED METHOD AND COMPOSITION FOR THE TREATMENT OF TRITERPENE SENSITIVE CONDITIONS, DISEASES OR DISORDERS

Publications (1)

Publication Number Publication Date
MX2020002884A true MX2020002884A (es) 2020-10-05

Family

ID=65630104

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002884A MX2020002884A (es) 2017-09-14 2018-09-04 Método y composición neuroprotectora mejorada para tratar afecciones neurológicas.

Country Status (11)

Country Link
US (2) US10722482B2 (enExample)
EP (1) EP3681477A4 (enExample)
JP (1) JP7370966B2 (enExample)
KR (1) KR20200083969A (enExample)
CN (1) CN111417384A (enExample)
AU (1) AU2018334467B2 (enExample)
CA (1) CA3075023A1 (enExample)
IL (1) IL273161A (enExample)
MX (1) MX2020002884A (enExample)
RU (1) RU2758376C2 (enExample)
WO (2) WO2019055245A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10702567B2 (en) 2016-09-14 2020-07-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
US10729735B1 (en) 2016-09-14 2020-08-04 Phoenix Biotechnology, Inc. Method and compostitions for treating coronavirus infection
US10596186B2 (en) 2016-09-14 2020-03-24 Phoenix Biotechnology, Inc. Method and compositions for treating viral infections
AU2018334467B2 (en) * 2017-09-14 2022-10-20 Phoenix Biotechnology, Inc. Method and improved neuroprotective composition for treating neurological conditions
US11331291B2 (en) * 2017-09-14 2022-05-17 Phoenix Biotechnology, Inc. Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection
WO2021202547A1 (en) * 2020-04-01 2021-10-07 Triterpenoid Therapeutics, Inc. Methods and compositions for treating and preventing viral infection
CN111888367A (zh) * 2020-07-31 2020-11-06 兰州大学 一种萜类化合物在制备增强蛋白酶体活性药物中的应用
US12357641B2 (en) * 2022-10-13 2025-07-15 Hong Kong Baptist University Identification of oleanolic acid and plant extract for glucose-6-phosphate dehydrogenase-related disorders including Bag3opathy

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US922078A (en) 1909-03-01 1909-05-18 Charles Burwell Benson Tongue-depressor.
DK166650B1 (da) 1991-03-15 1993-06-28 Aarhus Oliefabrik As Fedtbaser samt anvendelse af disse i kosmetiske og farmaceutiske emulsionsprodukter
US5977174A (en) 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US5985936A (en) 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
EP1079824B1 (en) 1998-05-19 2011-08-31 RESEARCH DEVELOPMENT FOUNDATION (a Nevada corporation) Triterpene compositions and methods for use thereof
ES2308979T3 (es) 1999-04-27 2008-12-16 Forbes Medi-Tech Inc. Procedimiento para la preparacion de una composicion de fitosteroles.
CN1129613C (zh) 1999-12-24 2003-12-03 中国科学院上海药物研究所 夹竹桃花多糖及其制备方法和应用
US20020077350A1 (en) 2000-08-01 2002-06-20 Ashni Naturaceuticals, Inc. Compositions exhibiting synergistic inhibition of the expression and/or activity of clyclooxygenase-2
US6629835B2 (en) * 2000-08-01 2003-10-07 Metaproteomics, Llc Combinations of diterpene triepoxide lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2
EP1309605A1 (en) 2000-08-18 2003-05-14 The Board Of Trustees Of The University Of Illinois Prodrugs of betulinic acid derivatives for the treatment of cancer and hiv
DE60204078T2 (de) 2001-04-09 2006-01-26 Loders Croklaan B.V. Konzentrat von Triterpenen
US7488722B2 (en) 2001-05-11 2009-02-10 University Of Ottawa Anxiolytic Marcgraviaceae compositions containing betulinic acid, betulinic acid derivatives, and methods
CA2487732C (en) 2002-05-28 2013-10-15 Bette Pollard Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
CN100518742C (zh) * 2003-10-10 2009-07-29 Sk化学株式会社 有效改善脑功能的三萜化合物
EP1694320B1 (en) * 2003-12-19 2008-07-09 Lipid Nutrition B.V. Use of compositions comprising oleanic acid and ursolic acid for the preparation of a medicament for the treatment of hypersensitivity and hyperreactivity
CA2560266A1 (en) 2004-03-17 2005-09-29 Panacos Pharmaceuticals, Inc. Pharmaceutical salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid
US7118508B2 (en) 2004-07-28 2006-10-10 General Motors Corporation Planetary transmissions having three interconnected gear members and clutched input members
WO2006044916A2 (en) 2004-10-18 2006-04-27 Bionaut Pharmaceuticals, Inc. Use of na+/ k+-atpase inhibitors and antagonists thereof
WO2006085334A2 (en) 2005-02-09 2006-08-17 Dabur Pharma Limited Novel betulinic acid derivatives a-ring-condensed to a heterocyclic group
WO2006105354A1 (en) 2005-03-29 2006-10-05 Regents Of The University Of Minnesota Selective oxidation of triterpenes employing tempo
US20060252733A1 (en) 2005-04-07 2006-11-09 Novelix Pharmaceuticals, Inc. Betulin, betulin derivatives, betulinic acid and betulinic acid derivatives as novel therapeutics in the treatment of disease of lipid and/or glucose metabolism
US20090131714A1 (en) 2005-06-08 2009-05-21 Krasutsky Pavel A Synthesis of betulonic and betulinic aldehydes
ES2469566T3 (es) 2005-06-10 2014-06-18 Pola Chemical Industries Inc. Nuevo derivado de ácido triterp�nico y preparación para aplicación externa para la piel que lo comprende
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
BRPI0619936A2 (pt) 2005-12-16 2011-10-25 Panacos Pharmaceuticals Inc preparação de sais farmacêuticos de ácido 3-o-(3',3'- dimetilsuccinil) betulìnico
EP1803461A1 (en) 2005-12-27 2007-07-04 Heinz-Herbert Fiebig Therapeutic use of an extract from the leaves of Nerium oleander
GB0604535D0 (en) 2006-03-07 2006-04-12 Sndv Sprl Betulonic acid derivatives
DE102006020582A1 (de) * 2006-05-03 2007-11-15 Gesellschaft zur Förderung der Krebstherapie e.V. Verfahren zur Herstellung einer triterpensäurehaltigen wässrigen Lösung, triterpensäurehaltige wässrige Lösung und deren Verwendung
WO2008063318A2 (en) 2006-10-12 2008-05-29 The Texas A & M University System And Safe Et Al Betulinic acid, derivatives and analogs thereof and uses therefor
US9505800B2 (en) 2006-11-03 2016-11-29 Myrexis, Inc. Extended triterpene derivatives
WO2008091532A1 (en) 2007-01-19 2008-07-31 Panacos Pharmaceuticals, Inc. Salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid and solid state forms thereof
US8987212B2 (en) 2007-08-07 2015-03-24 Muhammed Majeed Oleanoyl peptide composition and method of treating skin aging
EP2231165B1 (en) 2007-11-13 2013-05-15 Phoenix Biotechnology Inc. Method of determining the probability of a therapeutic response in cancer chemotherapy with cardiac glycoside
ES2326065B1 (es) 2008-03-28 2010-07-08 Consejo Superior De Investigaciones Cientificas (Csic) Utilizacion de un triterpeno pentaciclico para la preparacion de una composicion farmaceutica destinada al tratamiento de la esclerosis multiple.
BRPI0911422B8 (pt) 2008-04-18 2021-05-25 Reata Pharmaceuticals Inc compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos
EP2279197B1 (en) 2008-04-18 2014-11-05 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
US8124799B2 (en) 2008-04-18 2012-02-28 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
US20110224159A1 (en) 2008-09-10 2011-09-15 Universite du Quebec a Chicoutime Bidesmosidic betulin and betulinic acid derivatives and uses thereof as antitumor agents
US8778990B2 (en) 2008-11-04 2014-07-15 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
US8802727B2 (en) 2009-07-14 2014-08-12 Hetero Research Foundation, Hetero Drugs Limited Pharmaceutically acceptable salts of betulinic acid derivatives
TW201104501A (en) 2009-07-24 2011-02-01 Asustek Comp Inc Device and method for inputting Chinese character
CN101704872B (zh) 2009-11-23 2012-06-27 张南 23-羟基白桦酸衍生物、其制备方法及应用
US8685469B2 (en) 2009-11-30 2014-04-01 University Of Kwazulu-Natal In vitro anti-sickling activity of betulinic acid, oleanolic acid and their derivatives
AU2011203933B2 (en) 2010-01-11 2016-01-21 Phoenix Biotechnology, Inc. Method of treating neurological conditions with cardiac glycosides
US9011937B2 (en) 2010-11-22 2015-04-21 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
TWI386415B (zh) 2010-02-02 2013-02-21 Univ Kaohsiung Medical 熊果酸衍生物及其醫藥組合物
RU2606594C2 (ru) * 2010-11-22 2017-01-10 Феникс Байотекнолоджи, Инк. Способ лечения неврологических заболеваний экстрактом из видов nerium или видов thevetia
TWI410431B (zh) 2010-12-22 2013-10-01 Ind Tech Res Inst 齊敦果酸衍生物在製備預防或治療ｃ型肝炎之藥物的用途
WO2012095705A1 (en) 2011-01-10 2012-07-19 Hetero Research Foundation Pharmaceutically acceptable salts of novel betulinic acid derivatives
PL2670764T3 (pl) 2011-01-31 2016-02-29 Bristol Myers Squibb Co C-28 aminy zmodyfikowanych C-3 pochodnych kwasu betulinowego jako inhibitory dojrzewania HIV
CN102558280B (zh) 2011-11-18 2014-09-17 温州大学 一种30-卤代桦木酸的生产方法
WO2013079024A1 (zh) 2011-12-01 2013-06-06 杭州本生药业有限公司 齐墩果酸酰胺化衍生物、及其制备方法和应用
US9156801B2 (en) 2011-12-01 2015-10-13 Hangzhou Bensheng Pharmaceutical Co., Ltd. 2-substituted oleanolic acid derivative, method preparing for same, and application thereof
US20150119373A1 (en) 2012-04-24 2015-04-30 Hetero Research Foundation Novel betulinic acid derivatives as hiv inhibitors
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
KR101889528B1 (ko) 2012-08-14 2018-08-17 넥스올리고(주) 신규한 우르솔릭산 유도체 및 이의 제조 방법
DK2892911T3 (en) 2012-09-10 2017-10-23 Reata Pharmaceuticals Inc C17 heteroaryl derivatives of oleanolic acid and methods of use thereof
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
BR112015005168A2 (pt) 2012-09-10 2017-08-15 Reata Pharmaceuticals Inc Derivados de c17-alcanodiila e alquenodiila de ácido oleanólico e métodos de uso dos mesmos
WO2014105926A1 (en) 2012-12-31 2014-07-03 Hetero Research Foundation Novel betulinic acid proline derivatives as hiv inhibitors
BR112015019590A2 (pt) 2013-02-25 2017-07-18 Bristol Myers Squibb Co derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
EP2813221A1 (en) * 2013-06-13 2014-12-17 Natac Biotech, S.L. Combination of pentacyclic triterpenes and hydroxytyrosol and derivatives thereof
US10166246B2 (en) * 2014-05-27 2019-01-01 City Of Hope TGR5 agonist complexes for treating diabetes and cancer
US9920090B2 (en) 2014-06-19 2018-03-20 VIIV Healthcare UK (No.5) Limited Betulinic acid derivatives with HIV maturation inhibitory activity
WO2018053123A1 (en) 2016-09-14 2018-03-22 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
AU2018334467B2 (en) * 2017-09-14 2022-10-20 Phoenix Biotechnology, Inc. Method and improved neuroprotective composition for treating neurological conditions

Also Published As

Publication number Publication date
AU2018334467B2 (en) 2022-10-20
US10973785B2 (en) 2021-04-13
WO2019055245A9 (en) 2019-09-26
EP3681477A4 (en) 2021-06-09
JP7370966B2 (ja) 2023-10-30
WO2020050865A1 (en) 2020-03-12
IL273161A (en) 2020-04-30
WO2019055245A1 (en) 2019-03-21
RU2758376C2 (ru) 2021-10-28
RU2020113349A3 (enExample) 2021-10-14
JP2020534299A (ja) 2020-11-26
US10722482B2 (en) 2020-07-28
US20190076381A1 (en) 2019-03-14
AU2018334467A1 (en) 2020-04-16
US20210008017A1 (en) 2021-01-14
KR20200083969A (ko) 2020-07-09
CN111417384A (zh) 2020-07-14
EP3681477A1 (en) 2020-07-22
CA3075023A1 (en) 2019-03-21
RU2020113349A (ru) 2021-10-14

Similar Documents

Publication Publication Date Title
MX2020002884A (es) Método y composición neuroprotectora mejorada para tratar afecciones neurológicas.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
PH12019502793A1 (en) Aadc polynucleotides for the treatment of parkinson`s disease
MX2022010270A (es) Nuevo enfoque para tratar el cancer mediante el uso de la inmunomodulacion.
MX2023009483A (es) Anticuerpos monoclonales para usarse para el tratamiento de sinucleinopatia.
MX2017010544A (es) Metodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos del ojo.
PH12017500746B1 (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
PH12019500196A1 (en) Compounds and compositions and uses thereof
IL277182A (en) Compositions and methods for treating Parkinson's disease
MX2021006869A (es) Esteres de cromolin y usos de los mismos.
NZ753881A (en) Treatment of neurological diseases
MX2019009586A (es) Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal.
MX2024010655A (es) Uso de profarmacos de riluzol para tratar enfermedad de alzheimer.
MY208313A (en) Compositions and methods for treating brain injury
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
PH12019500198A1 (en) Compounds and compositions and uses thereof
MX2016008968A (es) Compuestos organicos.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MY205171A (en) Methods of treatment of hypertriglyceridemia
MX2019007041A (es) Metodos y composiciones para tratar la enfermedad de parkinson.
WO2017140684A3 (en) Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction
MX2020005438A (es) Formas de dosificacion de sulfato de morfina disuasivas del abuso.
WO2018026776A3 (en) Foxm1 modulators and uses thereof
MX2021009326A (es) Pridopidina de dosis baja para mal de parkinson y otras enfermedades asociadas con parkinsonismo.
MX2017012239A (es) Metodos y composiciones para la administracion intravenosa de fumaratos para el tratamiento de enfermedades neurologicas.